Tag: Novo Nordisk A/S

Drugmakers race to find a place in the next wave of obesity drugs

Jim Cramer says he can’t sell Eli Lilly despite its massive run up. Here’s why

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Weight loss drug maker sinks 25% after new safety data spooks investors

CVS to restore coverage of Zepbound, add Eli Lilly’s obesity pill to drug plans

Signos grows foothold in weight-loss wave fueled by GLP-1s with its AI health data tracking

Eli Lilly says next-generation weight loss drug clears crucial obesity trial

White House adds generic drugs to direct-to-consumer TrumpRx site

Medicare Coverage for GLP-1 Weight Loss Drugs: Cost, Eligibility and What to Know

Hantavirus outbreak isn’t another Covid pandemic – but experts say it’s testing U.S. readiness